Hepatocellular Carcinoma Size: Platelets, γ-Glutamyl Transpeptidase, and Alkaline Phosphatase

Oncology (Switzerland)

Volumn 85, Issue 3, 2013, Pages 153-159

  Carr, Brian I ^a   Guerra, Vito ^a  

^a NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

Glutamyl transpeptidase; Alkaline phosphatase; Fetoprotein; Hepatocellular carcinoma; Portal vein thrombosis; Terciles; Thrombocytopenia

Indexed keywords

ALKALINE PHOSPHATASE; BILIRUBIN; FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE; ALPHA FETOPROTEIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TUMOR VOLUME; ALPHA FETOPROTEIN BLOOD LEVEL; BILIRUBIN BLOOD LEVEL;

ALKALINE PHOSPHATASE; ALPHA-FETOPROTEINS; BILIRUBIN; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; ITALY; LIVER NEOPLASMS; MALE; PHENOTYPE; PLATELET COUNT; PROGNOSIS; PROSPECTIVE STUDIES; THROMBOCYTOPENIA; TUMOR BURDEN;

EID: 84885678913     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000354416     Document Type: Article

References (40)

1. Lok AS, Seef LB, Morgan TR, et al: Incidence of hepatocellular carcinoma and risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148
2. Wan DW, Tzimas D, Smith JA, et al: Risk factors for early-onset and late-onset hepatocellular carcinoma in Asian immigrants with hepatitis B in the United States. Am J Gastroenterol 2011; 106: 1994-2000
3. Yamanaka Y, Shiraki K, Miyahita K, et al: Risk factors for the recurrence of hepatocellular carcinoma after radiofrequency ablation of hepatocellular carcinoma in patients with hepatitis C. World J Gastroenterol 2005; 11: 2174-2178
4. Lu SN, Wang JH, Liu SL, et al: Thrombocytopenia as a surrogate for cirrhosis and a marker for the identification of patients at highrisk for hepatocellular carcinoma. Cancer 2006: 107: 2212-2222
5. Huang YC, Huang CF, Chang KC, et al: Community-based screening for hepatocellular carcinoma in elderly residents in a hepatitis B-and C-endemic area. J Gastroenterol Hepatol 2011; 26: 129-134
6. Ripoli C, Groszmann RJ, Garcia-Tsao G, et al: Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-928
7. Carr BI, Guerra V, Pancoska P: Thrombocytopenia in relation to tumor size in patients with hepatocellular carcinoma. Oncology 2012; 83: 339-345
8. Carr BI, Guerra V, De Giorgio M, Fagiuoli S, Pancoska P: Small hepatocellular carcinomas and thrombocytopenia. Oncology 2012; 83: 331-338
9. Zhao WC, Zhang HB, Yang N, et al: Preoperative predictors of short-term survival after hepatectomy for multinodular hepatocellular carcinoma. World J Gastroenterol 2012; 18: 3272-3781
10. Pompili M, Rapaccini GL, Covino M, et al: Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. Cancer 2001; 92: 126-135
11. Nomura F, Ohnishi K, Tanabe Y: Clinical features and prognosis of hepatocellular carcinoma with reference to serum alfa-fetoprotein levels: Analysis of 606 patients. Cancer 1989; 64: 1700-1707
12. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Cancer 1985; 56: 918-928
13. Hoshida Y, Villanueva A, Kobayashi M, et al: Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008; 359: 1995-2004
14. Utsonomiya T, Shimada M, Imura S, et al: Molecular signatures of noncancerous liver tissue can predict the risk for late recurrence of hepatocellular carcinoma. J Gastroenterol 2010: 45: 146-152
15. Fattovich G, Giustina G, Schalm SW, et al: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: the EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995; 21: 77-82
16. Lok AS, Seeff, LB, Morgan TR, et al: Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148
17. Kumada T, Toyoda H, Kiriyama S, et al: Incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection who have normal alanine aminotransferase values. J Med Virol 2010; 82: 539-545
18. Kawamura Y, Arase Y, Ikeda K, et al: Largescale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253-261
19. Nzeako UC, Goodman ZD, Ishak KG: Hepatocellular carcinoma in cirrhotic and noncirrhotic livers: a clinic-histopathologic study of 804 North American patients. Am J Clin Pathol 1996; 105: 65-75
20. Okuda K, Nakashima T, Kojiro M, et al: Hepatocellular carcinoma without cirrhosis in Japanese patients. Gastroenterology 1989; 97: 140-146
21. Trevisani F, D?Intino PE, Caraceni P, et al: Etiologic factors and clinical presentation of hepatocellular carcinoma: differences between cirrhotic and noncirrhotic Italian patients. Cancer 1995; 75: 2220-2232
22. Truant S, Boleslawsky E, Duhamel A, et al: Tumor size of hepatocellular carcinoma in noncirrhotic liver: a controversial predictive factor for outcome after resection. Eur J Surg Oncol 2012; 38: 1189-1196
23. Yom C, Chan KM, Lee CF, et al: Alkaline phosphatase: does it have a role in predicting hepatocellular carcinoma recurrence? J Gastrointest Surg 2011; 15: 1440-1449
24. Zhang JB, Chen Y, Zhang B, et al: Prognostic significance of serum gamma-glutamyl transferase in patients with intermediate hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Eur J Gastroenterol Hepatol 2011; 23: 787-793
25. Carr BI, Pancoska P, Branch RA: Significance of increased GGTP levels in HCC patients. Hepatogastroenterology 2010; 57: 869-874
26. Zucker ML, Hagedorn CH, Murphy CA, et al: Mechanism of thrombocytopenia in chronic hepatitis C as evaluated by the immature platelet fraction. Int J Lab Hematol 2012; 34: 525-532
27. Campbell JS, Hughes SD, Gilbertson DG, et al: Platelet-derived growth factor C induces liver fibrosis, steatosis and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005; 102: 3389-3394
28. Gotzmann J, Fischer AN, Zoler M, et al: A crucial function of PDGF in TGF-beta-mediated cancer progression of hepatocytes. Oncogene 2006; 25: 3170-3185
29. Stock P, Monga D, Tan X, et al: Platelet-derived growth factor receptor-alpha: a novel therapeutic target in human hepatocellular cancer. Mol Cancer Ther 2007; 6: 1932-1941
30. Maass T, Thieringer FR, Mann A, et al: Liver specific overexpression of platelet-derived growth factor-B accelerates liver cancer development in chemically induced liver carcinogenesis. Int J Cancer 2011; 128: 1259-1268
31. Okada H, Honda M, Campbell JS, et al: Acyclic retinoid targets platelet-derived growth factor signaling in the prevention of hepatic fibrosis and hepatocellular carcinoma development. Cancer Res 2012; 72: 4459-4471
32. Soll C, Jang JH, Riener MD, et al: Serotonin promotes tumor growth in human hepatocellular cancer. Hepatology 2010; 51: 1244-1254
33. Lesurtel M, Clavien P-A: Serotonin: a key molecule in acute and chronic liver injury. Clin Res Hepatol Gastroenterol 2012; 36: 319-322
34. Zhou J, Tang YZ, Fan J, et al: Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 2000; 126: 57-61
35. Gaughofer C, Sagmeister S, Schrottmaier W, et al: Up-regulation of the fibroblast growth factor subfamily in human hepatocellular carcinoma for cell survival and neoangiogenesis. Hepatology 2011; 53: 854-864
36. Sitia G, Aiolfi R, Di Lucia P, et al: Antiplatelet therapy prevents hepatocellular carcinoma and improves survival in a mouse model of chronic hepatitis B. Proc Natl Acad Sci USA 2012; 109:E2165-E2172
37. Gurdol F, Nwose OM, Mikhailidis DP: Gamma-glutamyl transferase activity in human platelets: quantification of activity, isoenzyme characterization and potential clinical relevance. Platelets 1995; 6: 200-203
38. Ansell BF Jr, Scott RB: Platelet alkaline phosphatase: normal values and variations in myeloproliferative syndromes. Proc Soc Exp Biol Med 1969; 130: 1119-1121
39. Hwang SJ, Luo JC, Li CP et al: Thrombocytosis: a paraneoplastic syndrome in patients with hepatocellular carcinoma. World J Gastroenterol 2004; 10: 2472-2477
40. Carr BI, Guerra V: Thrombocytosis and hepatocellular carcinoma. Dig Dis Sci 2013; 58: 1790-1796